Drug repositioning and its aspects in clinical diabetology

被引:0
作者
Pokoly, Bence [1 ,2 ]
Somogyi, Aniko [3 ]
机构
[1] Orszag Reumatol Fizioterap Int, Orszag Mozgasszerv Int, Budapest, Hungary
[2] Szent Margit Korhaz, Budapest, Hungary
[3] Semmelweis Egyet, Altalan Orvostudomany Kar, Belgyogyaszat Hematol Klinika, Budapest, Hungary
关键词
drug repositioning; diabetes mellitus; treatment; CARDIOVASCULAR OUTCOMES; THALIDOMIDE; LIRAGLUTIDE;
D O I
10.1556/650.2024.33177
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Drug repositioning is a special and increasingly utilized way of drug development. As a result of the procedure, drugs and active ingredients that are already on the market for the treatment of certain diseases or are in various phases of development are being successfully used with new indications, some of which are sometimes completely different from the original ones. In the first half of our review, we give a brief overview of this process, outline its various advantages and potential pitfalls. After the general introductory part, we will examine the more successful areas of application of the drugs that were previously marketed as antidiabetics, and then we will mention some preparations that can now also be used in the treatment of diabetes mellitus, due to their significant blood sugar lowering properties that have been recognized in the meantime. Orv Hetil. 2024; 165(49): 1919-1926.
引用
收藏
页码:1919 / 1926
页数:8
相关论文
共 58 条
[1]   Empagliflozin in Heart Failure with a Preserved Ejection Fraction [J].
Anker, Stefan D. ;
Butler, Javed ;
Filippatos, Gerasimos ;
Ferreira, Joao P. ;
Bocchi, Edimar ;
Boehm, Michael ;
Brunner-La Rocca, Hans-Peter ;
Choi, Dong-Ju ;
Chopra, Vijay ;
Chuquiure-Valenzuela, Eduardo ;
Giannetti, Nadia ;
Gomez-Mesa, Juan Esteban ;
Janssens, Stefan ;
Januzzi, James L. ;
Gonzalez-Juanatey, Jose R. ;
Merkely, Bela ;
Nicholls, Stephen J. ;
Perrone, Sergio V. ;
Pina, Ileana L. ;
Ponikowski, Piotr ;
Senni, Michele ;
Sim, David ;
Spinar, Jindrich ;
Squire, Iain ;
Taddei, Stefano ;
Tsutsui, Hiroyuki ;
Verma, Subodh ;
Vinereanu, Dragos ;
Zhang, Jian ;
Carson, Peter ;
Lam, Carolyn Su Ping ;
Marx, Nikolaus ;
Zeller, Cordula ;
Sattar, Naveed ;
Jamal, Waheed ;
Schnaidt, Sven ;
Schnee, Janet M. ;
Brueckmann, Martina ;
Pocock, Stuart J. ;
Zannad, Faiez ;
Packer, Milton .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (16) :1451-1461
[2]   Drug repositioning: Identifying and developing new uses for existing drugs [J].
Ashburn, TT ;
Thor, KB .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (08) :673-683
[3]   Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition? [J].
Balasubramanian, Priyadarshini ;
Wanner, Christoph ;
Ferreira, Joao Pedro ;
Ofstad, Anne Pernille ;
Elsaesser, Amelie ;
Zinman, Bernard ;
Inzucchi, Silvio E. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (07) :E3003-E3007
[4]   SGLT2 Inhibitors as Potential Anticancer Agents [J].
Basak, Debasish ;
Gamez, David ;
Deb, Subrata .
BIOMEDICINES, 2023, 11 (07)
[5]   Rediscovery of pioglitazone [J].
Bence, Pokoly ;
Aniko, Somogyi .
ORVOSI HETILAP, 2023, 164 (26) :1012-1019
[6]   Overcoming the legal and regulatory barriers to drug repurposing [J].
Breckenridge, Alasdair ;
Jacob, Robin .
NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (01) :1-2
[7]   Metformin: Past, Present, and Future [J].
Chaudhary, Sandeep ;
Kulkarni, Amitabh .
CURRENT DIABETES REPORTS, 2024, 24 (06) :119-130
[8]   Review of COVID-19 Therapeutics by Mechanism: From Discovery to Approval [J].
Choi, Hee Sun ;
Choi, A. Young ;
Kopp, Jeffrey B. ;
Winkler, Cheryl A. ;
Cho, Sung Kweon .
JOURNAL OF KOREAN MEDICAL SCIENCE, 2024, 39 (14)
[9]   Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales [J].
Dahlen, Amelia D. ;
Dashi, Giovanna ;
Maslov, Ivan ;
Attwood, Misty M. ;
Jonsson, Joergen ;
Trukhan, Vladimir ;
Schioth, Helgi B. .
FRONTIERS IN PHARMACOLOGY, 2022, 12
[10]   SGLT2 inhibitors: cardiorenal metabolic drugs for the ages [J].
Defronzo, Ralph A. .
JOURNAL OF CLINICAL INVESTIGATION, 2024, 134 (05)